Table 2.
Summary of clinical syndromes and associated conditions in patients with GFAP Astrocytopathy.
| Feature | Incidence | Slow wave+epileptiform discharge | 6/31 (19.35%) |
|---|---|---|---|
| Males: females | 23:12 | Neuroimaging | |
| Mean age | 6.3 ± 0.6 | Brain | 29/35 (82.86%) |
| Intensive care unit | 11/35 (31.43%) | Periventricular radial linear enhancement |
3/35 (8.57%) |
| Early symptoms (runny nose, sore throat, cough, etc.) | 9/35 (25.71%) | enhancement of other parts | 12/35 (34.29%) |
| Clinical syndrome | spinal cord | 9/35 (25.71%) | |
| Meningoencephalitis | 20/35 (57.14%) | optic nerve | 7/35 (20%) |
| Meningeal encephalomyelitis | 7/35 (20%) | CSF | |
| Myelitis | 1/35 (2.86%) | Normal leukocyte | 12/35 (34.29%) |
| Main symptoms | Elevated leukocyte | 23/35 (65.71%) | |
| Fever | 22/35 (62.86%) | Tumor | 2/35 (5.71%) |
| Headache | 15/35 (42.86%) | Multiple antibodies positive | 11/35 (31.43%) |
| Seizures | 15/35 (42.86%) | Therapy | |
| psychosis | 18/35 (51.43%) | IVMP | 7/35 (20%) |
| Disorder of consciousness | 19/35 (54.29%) | IVIG | 3/35 (8.57%) |
| optic neuritis | 8/35 ( (22.86%) | IVMP+IVIG | 21/35 (60%) |
| ataxia | 4/35 (11.43%) | IVMP, IVIG+Second-line immunomodulatory therapy | 4/35 (11.43%) |
| dyskinesia | 14/35 (40.00%) | IVMP,IVIG+PLEX | 1/35 (2.86%) |
| Autonomic nerve dysfunction | 9/35 (25.71%) | mRS | |
| peripheral nerve damage | 3/35 (8.57%) | On admission mRS (0-3) | 17/35 (48.57%) |
| EEG findings | On admission mRS (4-5) | 18/35 (51.43%) | |
| Normal | 5/31 (16.12%) | At discharge mRS (0-2) | 26/35 (74.29%) |
| Slow wave background | 19/31 (61.29%) | At discharge mRS (3-5) | 9/35 (25.71%) |